Actos Bladder Cancer Lawsuit Update: First Federal Trial Set for November 2014

Share Article

First Actos bladder cancer lawsuit in federal Actos litigation set for trial in November 2014, Bernstein Liebhard LLP reports.

Bernstein Liebhard LLP | Consumer Injury Lawyers
Those who developed bladder cancer as a result of taking Actos may be able to collect compensation for medical expenses, lost wages, pain and suffering, and more.

Actos bladder cancer lawsuits are moving towards trial in the federal consolidated Actos litigation, In re: Actos (Pioglitazone) Products Liability Litigation (“MDL No. 2299”), Bernstein Liebhard LLP reports.* The federal multidistrict litigation is currently pending before the Honorable Rebecca Doherty in the U.S. District Court for the Western District of Louisiana. The Court’s order, which was issued on July 13, 2012, sets out deadlines for the course of the Actos litigation. According to the order, the first federal Actos bladder cancer lawsuit trial is scheduled to begin on November 3, 2014 with the second trial set for July 8, 2015.    

Plaintiffs involved in the Actos litigation allege that the drug, prescribed to treat type-2 diabetes and manufactured by Takeda Pharmaceuticals, caused them to develop bladder cancer. Bernstein Liebhard LLP, a nationwide law firm representing clients who have been injured by dangerous drugs and defective medical devices, is currently evaluating and investigating potential Actos claims.

As described in the scheduling order, lawyers for plaintiffs and defendants must select the potential trial cases by June 3, 2013. The parties will have until September 30, 2013 to complete core discovery in these cases. Selection of the Actos bladder cancer lawsuits that will go to trial will follow on October 16, 2013.

Discovery Rules Ordered To Ensure The Actos Litigation Proceeds Expeditiously

Although the first Actos bladder cancer lawsuit is more than two years away, according to the order, Judge Doherty issued these deadlines given the scope of the proceedings, the number of plaintiffs who have already filed cases, the number of lawsuits expected to be filed, the amount of discovery that will be required, and the time necessary to complete pretrial preparations in order to meet the targeted dates for the initial bellwether trials. In addition, to ensure that these first Actos bladder cancer lawsuits go forward as scheduled, Judge Doherty also issued detailed discovery deadlines regarding depositions and motion practice.

Those who developed bladder cancer as a result of taking Actos may be able to collect compensation for medical expenses, lost wages, pain and suffering, and more. Learn more about the Actos litigation by visiting our website, http://www.consumerinjurylawyers.com. For more information, contact a lawyer at Bernstein Liebhard LLP today at (877) 779-1414.

*lawd.uscourts.gov/MDL2299/11-md-2299.071312.so.cg.pdf

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past nine consecutive years. Only two firms in the country have been selected for the Hot List nine years in a row.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(877) 779-1414

ATTORNEY ADVERTISING. © 2012 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Amy L. Abate. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
###

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info@consumerinjurylawyers.com
http://www.consumerinjurylawyers.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Visit website